{"_links": {"parentPackage": {"href": "/mdr/ct/packages/protocolct-2021-12-17", "title": "Protocol Controlled Terminology Package 48 Effective 2021-12-17", "type": "Terminology"}, "priorVersion": {"href": "/mdr/ct/packages/protocolct-2021-09-24/codelists/C170441", "title": "CDISC Protocol Endpoint Type Value Set Terminology", "type": "Code List"}, "rootItem": {"href": "/mdr/root/ct/protocolct/codelists/C170441", "title": "Version-agnostic anchor resource for codelist C170441", "type": "Root Value Domain"}, "self": {"href": "/mdr/ct/packages/protocolct-2021-12-17/codelists/C170441", "title": "CDISC Protocol Endpoint Type Value Set Terminology", "type": "Code List"}}, "conceptId": "C170441", "definition": "The terminology relevant to the type of endpoint for the study.", "name": "Endpoint Type Value Set Terminology", "preferredTerm": "CDISC Protocol Endpoint Type Value Set Terminology", "submissionValue": "Endpoint Type Value Set Terminology", "synonyms": ["Endpoint Type Value Set Terminology"], "terms": [{"conceptId": "C170561", "definition": "Endpoint(s) constructed from two or more endpoints that represents an overall clinically relevant measure of clinical benefit.", "preferredTerm": "Composite Endpoint", "submissionValue": "Composite Endpoint", "synonyms": ["Combined Endpoint"]}, {"conceptId": "C170560", "definition": "Endpoint(s) used in clinical studies to directly measure how a patient feels, functions, or survives. These endpoint(s) in themselves represent or characterize the clinical outcome of interest. (FDA: https://www.fda.gov/media/84987/download)", "preferredTerm": "Direct Endpoint", "submissionValue": "Direct Endpoint"}, {"conceptId": "C170559", "definition": "Endpoint(s) that may include clinically important events that are expected to occur too infrequently to show a treatment effect or endpoints that for other reasons are thought to be less likely to show an effect but are included to explore new hypotheses. (After FDA-NIH Protocol Template)", "preferredTerm": "Exploratory Endpoint", "submissionValue": "Exploratory Endpoint"}, {"conceptId": "C94496", "definition": "Endpoint(s) of greatest importance that is the basis for concluding whether the study met its objective(s) and provides a clinically relevant, valid, and reliable measure of the primary objective(s). (After FDA-NIH Protocol Template)", "preferredTerm": "Primary Endpoint", "submissionValue": "Primary Endpoint"}, {"conceptId": "C139173", "definition": "Endpoint(s) that may provide supportive information about the effect of the study intervention(s) on the primary endpoint or demonstrate additional effects on the disease or condition. (After FDA-NIH Protocol Template)", "preferredTerm": "Secondary Endpoint", "submissionValue": "Secondary Endpoint"}, {"conceptId": "C68772", "definition": "Endpoint(s) used in clinical studies as a substitute for a direct measure of how a patient feels, functions, or survives. A surrogate endpoint is expected to predict clinical benefit or harm based on epidemiologic, therapeutic, pathophysiologic, or other scientific evidence. A surrogate endpoint does not measure the clinical benefit of primary interest in and of itself. (After NIH-FDA BEST (Biomarkers, Endpoints, and other Tools) Resource, https://www.ncbi.nlm.nih.gov/books/NBK338448/)", "preferredTerm": "Surrogate Endpoint", "submissionValue": "Surrogate Endpoint"}]}